Top

BMC Psychiatry

Published in:

Open Access 01-12-2018 | Research article

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis

Authors: Peng Men, Zhanmiao Yi, Chaoyun Li, Shuli Qu, Tengbin Xiong, Xin Yu, Suodi Zhai

Published in: BMC Psychiatry | Issue 1/2018

Abstract

Background

Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia in China. Since more Chinese patients are gaining access to amisulpride, the study aims to compare the efficacy, safety, and costs between amisulpride and olanzapine for schizophrenia treatment in China.

Methods

PubMed, Embase, the Cochrane library, China National Knowledge Infrastructure (CNKI) and WanFang database were systematically searched for randomized controlled trials (RCTs) up to July 2018. The Cochrane Risk of Bias tool was utilized to assess the quality of included studies. A meta-analysis was performed to compare the efficacy and safety of amisulpride and olanzapine, followed by a cost-minimization analysis using local drug and medical costs reported in China.

Results

Twenty RCTs with 2000 patients were included in the systematic review. There were no significant differences between amisulpride and olanzapine on efficacy measures based on scores from the Positive and Negative Syndrome Scale, the Scale for the Assessment of Negative Symptoms, the Brief Psychiatric Rating Scale and the Clinical Global Impressions-Severity or Improvement. For safety outcomes, amisulpride was associated with lower fasting blood glucose and less abnormal liver functions as well as significantly lower risks of weight gain, constipation, and somnolence; olanzapine was associated with significantly lower risks of insomnia and lactation/amenorrhea/sexual hormone disorder. No significant differences were found in risks of extrapyramidal symptoms (EPS), tremor, akathisia, abnormal corrected QT interval. Cost-minimization analysis showed that amisulpride was likely to be a cost-saving alternative in China, with potential savings of 1358 Chinese Yuan (CNY) per patient for a three-month schizophrenia treatment compared with olanzapine.

Conclusion

As the first meta-analysis and cost-minimization analysis comparing the efficacy, safety and cost of amisulpride and olanzapine within a Chinese setting, the study suggests that amisulpride may be an effective, well-tolerated, and cost-saving antipsychotic drug alternative in China.

Schizophrenia overview. https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. Accessed 26 Apr 2018.

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–602. https://doi.org/10.1016/S0140-6736(16)31678-6. PMID: 27733282CrossRef

Chan KY, Zhao F-F, Meng S, Demaio AR, Reed C, Theodoratou E, et al. Prevalence of schizophrenia in China between 1990 and 2010. J Glob Health. 2015;5:010410. https://doi.org/10.7189/jogh.05.010410. PMID: 26649171CrossRefPubMedPubMedCentral

Long J, Huang G, Liang W, Liang B, Chen Q, Xie J, et al. The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys. Acta Psychiatr Scand. 2014;130:244–56. https://doi.org/10.1111/acps.12296. PMID: 24916190CrossRefPubMed

Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H. The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy. Clinicoecon Outcomes Res. 2013;5:407–18. https://doi.org/10.2147/CEOR.S44325. PMID: 23983478CrossRefPubMedPubMedCentral

Nicholl D, Akhras K, Diels J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin. 2010;26:943–55.CrossRefPubMed

Chong HY, Teoh SL, DB-C W, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016; https://doi.org/10.2147/NDT.S96649.

Wu J, He X, Liu L, Ye W, Montgomery W, Xue H, et al. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China. Neuropsychiatr Dis Treat. 2015;11:983–90. https://doi.org/10.2147/NDT.S76231. PMID: 25897235CrossRefPubMedPubMedCentral

Zhao J, Shi S. Chinese guidelines for the prevention and treatment of schizophrenia (version 2). 2015.

10.

Research and Markets. Investigation Report on China’s Olanzapine Market 2015–2019. 2015. https://www.prnewswire.com/news-releases/investigation-report-on-chinas-olanzapine-market-2015-2019-300125449.html. Accessed 26 Apr 2018.

11.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624. https://doi.org/10.1002/14651858.CD006624.pub2. PMID: 20091599CrossRef

12.

Lin L, Zhao YJ, Zhou HJ, Khoo AL, Teng M, Soh LB, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31:84–92. https://doi.org/10.1097/YIC.0000000000000111. PMID: 26619182CrossRefPubMed

13.

García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, Alcalde J, Oyagüez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2:8. https://doi.org/10.1186/2191-1991-2-8. PMID: 22828390CrossRefPubMedPubMedCentral

14.

Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61:1979–88. https://doi.org/10.1111/j.1742-1241.2007.01431.x.CrossRefPubMed

15.

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: http://handbook.cochrane.org. Accessed 26 Apr 2018.

16.

The guidelines manual | Guidance and guidelines | NICE. https://www.nice.org.uk/process/pmg6/chapter/introduction. Accessed 26 Apr 2018.

17.

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. PMID: 22008217CrossRefPubMedPubMedCentral

18.

Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand. 2006;114:319–27. https://doi.org/10.1111/j.1600-0447.2006.00887.x. PMID: 17022791CrossRefPubMed

19.

Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377–82. https://doi.org/10.1111/j.1365-2125.2010.03783.x. PMID: 21284696CrossRefPubMedPubMedCentral

20.

Bhowmick S, Hazra A, Ghosh M. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Aust N Z J Psychiatry. 2010;44:237–42. https://doi.org/10.3109/00048670903487134. PMID: 20050717CrossRefPubMed

21.

Chu W, Chen Y, Zhao Y, Zhao B, Xu Z, Qiu R, et al. A comparison of six kinds of antipsychotic drugs′effects on the cognitive function in patients with first episode schizophrenia. J Clin Psychiatry. 2015;25:197–9. https://bit.ly/2KdKgFX. Accessed 26 Apr 2018

22.

Guo W, Xu H, Zhang X. A randomized and comparative study of amisulpride and olanzapine in treatment of schizophrenia. J Neurosci Ment Health. 2012;12:284–6. https://doi.org/10.3969/j.issn.1009-6574.2012.03.022. CrossRef

23.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–97. https://doi.org/10.1016/S0140-6736(08)60486-9. PMID: 18374841CrossRefPubMed

24.

Kong Y, Song Y. A control study of amisulpride vs.olanzapine in the treatment of first-episode schizophrenia. J Cli Psychosom Dis. 2014;20:34–35,40. https://doi.org/10.3969/j.issn.1672-187X.2014.06.014-0034-03.CrossRef

25.

Li B, Chi Z, Chen B, Yan C. Effects of amisulpride, paliperidone extendedrelease tablets, olanzapine on cognitive and memory function of patients with first-episode schizophrenia and without medication. J Inte Tional Psychiatry. 2015;42:14–7. https://bit.ly/2JrAMWn. Accessed 26 Apr 2018.

26.

Li F, Zheng X, Feng W. A control study on amisulpride and olanzapine in first episode patients with schizophrenia. 2014;24:121–2. https://bit.ly/2FeQDFm. Accessed 26 Apr 2018.

27.

Lin H, Miao H. Clinical observation of amoxicillin and olanzapine in the treatment of acute schizophrenia. J Mod Clin Med. 2015;41:130–1. https://doi.org/10.11851/j.issn.1673-1557.2015.02.018. CrossRef

28.

Liu X, Jin S, Li W. A control study of amisulpride vs olanzapine in the treatment of female schizophrenia. J Clin Psychosom Dis. 2015;21 https://doi.org/10.3969/j.issn.1672-187X.2015.02.012-0035-03.

29.

Lv Z, Zhou Z, Zhang Y. The treatment of female schizophrenia using Amisulpride and olanzapine. China J Health Psychol. 2014;22:499–501. https://doi.org/10.13342/j.cnki.cjhp.2014.04.009. CrossRef

30.

Mortimer A, Martin S, Lôo H, Peuskens J, SOLIANOL Sudy Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19:63–9. PMID: 15076013CrossRefPubMed

31.

Pawar GR, Phadnis P, Paliwal A. Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial. ISRN Psychiatry. 2012;2012:703751. https://doi.org/10.5402/2012/703751. PMID: 23738210CrossRefPubMedPubMedCentral

32.

Sun X, Yang J. The curative effects of amisulpride and olanzapine on acute schizophrenia. Chin J Prev Contr Chron Dis. 2013;21:292–3. 296. https://doi.org/10.16386/j.cjpccd.issn.1004-6194.2013.03.048.CrossRef

33.

Vanelle J-M, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 2006;21:523–30. https://doi.org/10.1016/j.eurpsy.2006.09.003. PMID: 17113759CrossRefPubMed

34.

Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn K-U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology. 2005;30:381–90. https://doi.org/10.1038/sj.npp.1300626. PMID: 15578006CrossRefPubMed

35.

Yang D, Chen J, Chen Y, Peng H. Comparative study of Amisulpride vs .Olanzapine for the treatment of schizophrenia. J Clin Res. 2014;31:479–480,483. https://doi.org/10.3969/j.issn.1671-7171.2014.03.022.CrossRef

36.

Yang F, Zhang C, Wen L. A control study of amisulpride vs olanzapine in the treatment of schizophrenia characterized by negative symptoms. J Clin Psychosom Dis. 2015;21:32–34,48. https://doi.org/10.3969/j.issn.1672-187X.2015.02.011-0032-04.CrossRef

37.

Yao K, Zhou Q, Sui Y. A comparative study of sulforam and olanzapine on first - episode schizophrenia. Anhui Med J. 2016;37:80–2. https://doi.org/10.3969/j.issn.1000-0399.2016.01.026. CrossRef

38.

Yi J, Hu Y, Wan Q. Comparative study on effects of amisulpride and olanzapine on glucose and lipid metabolism in patients with aged schizophrenia. J Neurosci Ment Health. 2014;14:400–402,405. https://doi.org/10.3969/j.issn.1009-6574.2014.04.022.CrossRef

Title: Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
Authors: Peng Men
Zhanmiao Yi
Chaoyun Li
Shuli Qu
Tengbin Xiong
Xin Yu
Suodi Zhai
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-018-1867-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Extending research on Emotion Regulation Individual Therapy for Adolescents (ERITA) with nonsuicidal self-injury disorder: open pilot trial and mediation analysis of a novel online version

Prevalence of depression or depressive symptoms among people living with HIV/AIDS in China: a systematic review and meta-analysis

The impact of immigration detention on mental health: a systematic review

Prevalence of orthorexia nervosa in university students and its relationship with psychopathological aspects of eating behaviour disorders

A smartphone application for treating depressive symptoms: study protocol for a randomised controlled trial

Major anxiety disorders in Iran: prevalence, sociodemographic correlates and service utilization